Daniel Lu

Daniel Lu is a Senior Scientist II at Biomea Fusion since October 2020, with prior experience as a Scientist II at Pharmacyclics, an AbbVie Company, from February 2014 to October 2020, where notable contributions included the co-development of Flow Cytometry-based ADCC and ADCP assays and involvement in over 20 immuno-oncology in-vivo studies. Daniel's academic background includes a Master's degree in Biology and a Bachelor's degree in Biochemistry, both from the University of the Pacific. While at the University of the Pacific, Daniel also served as a Master Student and Teaching Assistant, focusing on the expression of Rad51 and NBS1 in various models, and held the role of ALANA Center Outreach Coordinator, managing initiatives to promote diversity and inclusion.